<?xml version="1.0" encoding="UTF-8"?>
<p>In patients with DCM, CD34
 <sup>+</sup> cell therapy appears to be associated with increased IVS viability and improved RV function. Further studies are warranted to verify our preliminary findings, better define the underlying mechanisms, and investigate whether or not this therapeutic approach could offer benefit in a broader population of patients with chronic heart failure and RV dysfunction.
</p>
